Distal Pancreatectomy Pancreatic Fistula Risk Prediction Model Validation Study
Launched by UNIVERSITY OF EDINBURGH · Feb 10, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the risk of developing a complication called pancreatic fistula after a surgery known as distal pancreatectomy, where part of the pancreas is removed. Researchers want to compare and improve two recently developed risk prediction tools, called DISPAIR and D-FRS, to help doctors better understand which patients are at higher risk for this complication. By doing this, they hope to make the surgery safer for everyone.
To participate in this study, you need to be between 18 and 99 years old and have had a distal pancreatectomy since January 1, 2020. Unfortunately, if you are under 18 or over 99, or if you have had any pancreatic surgery before, you won't be eligible to join. If you decide to take part, you can expect to share some information about your health and surgery, which will help researchers learn more about how to predict and possibly prevent this complication in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 to 99 years old
- • Underwent distal pancreatectomy after 1/1/2020
- Exclusion Criteria:
- • Under 18 years old
- • 100 years old or older
- • Previous pancreatic surgery prior to distal pancreatectomy
About University Of Edinburgh
The University of Edinburgh, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a leading clinical trial sponsor dedicated to advancing healthcare through rigorous scientific inquiry. With a strong emphasis on multidisciplinary collaboration, the university facilitates cutting-edge clinical studies that aim to explore novel therapies and improve patient outcomes. Leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, the University of Edinburgh is at the forefront of translating scientific discoveries into practical applications, thereby contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edinburgh, , United Kingdom
Patients applied
Trial Officials
Ville Sallinen, MD PhD
Study Chair
Helsinki University Hospital and University of Helsinki
Stephen J Wigmore, MD FRCSED
Principal Investigator
University of Edinburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials